Loading organizations...
Neuraltus Pharmaceuticals develops therapies for neurodegenerative diseases by targeting immune system modulation. Its primary asset, NP001, is a small molecule immune regulator designed to temper systemic inflammation believed to drive disease progression. The company focuses on the compound's ability to modulate macrophage activity, aiming to mitigate the inflammatory response in affected individuals.
The company was established in 2004 by founder Michael McGrath. The foundational insight stemmed from the growing understanding of the role systemic inflammation plays in the pathology of severe neurological conditions. This recognition fueled the development of NP001 as a potential therapeutic intervention to address these underlying inflammatory mechanisms.
Neuraltus Pharmaceuticals aims to serve patients suffering from neurodegenerative diseases, with an initial focus on Amyotrophic Lateral Sclerosis (ALS). The company's vision is centered on advancing innovative treatments that address the complex inflammatory processes involved in neurological disorders, striving to improve outcomes for patient populations with limited therapeutic options.
Neuraltus Pharmaceuticals has raised $42.0M across 3 funding rounds.
Neuraltus Pharmaceuticals has raised $42.0M in total across 3 funding rounds.
Neuraltus Pharmaceuticals has raised $42.0M in total across 3 funding rounds.
Neuraltus Pharmaceuticals's investors include Johnson & Johnson Innovation, New Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company focused on developing innovative therapeutics for neurodegenerative diseases. It builds drug candidates aimed at addressing serious neurological conditions, serving patients with unmet medical needs in this challenging therapeutic area. The company has demonstrated growth momentum through advancing multiple clinical trials and building a robust drug pipeline targeting neurodegeneration[1][2][3][4].
Founded in 2004 and headquartered in San Bruno, California, Neuraltus Pharmaceuticals was established by founders with expertise in neuroscience and drug development. The idea emerged from the need to create effective treatments for neurodegenerative disorders, a field with significant unmet demand. Early traction came from progressing promising drug candidates into clinical development, positioning the company as a focused innovator in neurological therapeutics[2][4].
Neuraltus rides the growing trend of precision medicine and targeted therapies for neurological disorders, a field gaining momentum due to aging populations and increasing prevalence of diseases like Alzheimer’s and Parkinson’s. The timing is critical as advances in neuroscience, biomarker identification, and drug delivery technologies converge to enable new treatment possibilities. Market forces such as rising demand for effective neurotherapeutics and increased investment in biotech innovation work in Neuraltus’s favor. The company contributes to the broader ecosystem by pushing forward novel approaches that could redefine neurodegenerative disease treatment paradigms[1][3][4].
Looking ahead, Neuraltus Pharmaceuticals is poised to continue advancing its clinical pipeline, potentially bringing new therapies closer to market approval. Trends shaping its journey include breakthroughs in neurobiology, regulatory support for innovative neurological drugs, and growing patient advocacy for better treatments. As it matures, Neuraltus’s influence may expand through partnerships, licensing, or eventual commercialization, reinforcing its role as a key player in neurodegenerative disease therapeutics. This trajectory ties back to its founding mission of addressing critical unmet needs in neurological health with cutting-edge science[1][2][3][4].
Neuraltus Pharmaceuticals has raised $42.0M across 3 funding rounds. Most recently, it raised $15.0M Series U in May 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2016 | $15M Series U | — | Johnson & Johnson Innovation, NEW Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners | Announced |
| Jan 1, 2012 | $10M Series B | — | Johnson & Johnson Innovation, NEW Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners | Announced |
| Mar 1, 2009 | $17M Series A | — | Johnson & Johnson Innovation, NEW Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners | Announced |
